The FDA recently approved the first 3D printed drug – SPRITAM® levetiracetam for oral use as a prescription adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and primary generalized tonic-clonic seizures in adults and children with epilepsy. Aprecia Pharmaceuticals, the developer of the drug, devised a way of producing individually dosed tablets that dissolve on contact with liquid.
“ZipDose Technology enables the delivery of a high drug load, up to 1,000 mg in a single dose.2 As a result, SPRITAM enhances the patient experience – administration of even the largest strengths of levetiracetam with just a sip of liquid. In addition, with SPRITAM there is no measuring required as each dose is individually packaged, making it easy to carry this treatment on the go.”
Full article here: http://tinyurl.com/p49pard